The cytokine network in rheumatoid arthritis: Definition of TNFα as a therapeutic target

Journal of the Royal College of Physicians of London

Volumn 30, Issue 6, 1996, Pages 560-570

  Feldmann, Marc ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DRUG ANTAGONISM; FEMALE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MOUSE; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; RECEPTORS, CYTOKINE; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030276893     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Hypothesis: role of aberrant HLA-DR expression and antigen presentation in the induction of endocrine autoimmunity. Lancet 1983;ii:1115-9.
2. Steinman L. Autoimmune disease. Sci Am 1993;269:107-14.
3. Tisch R, McDevitt H. Insulin dependent diabetes mellitus. Cell 1996;85:291-7.
4. Steinman L. Multiple sclerosis: a co-ordinated immunological attack against myelin in the central nervous system. Cell 1996;85:299-302.
5. Goodnow CC. Balancing immunity and tolerance: Deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 1996;93: 2264-71.
6. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity? J Exp Med 1995;181:1945-8.
7. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
8. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
9. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TXFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;ii: 244-7.
10. Feldmann M, Brennan FM, Chantry D, Haworth C, et al. Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 1990;49:480-6.
11. Erhardt CC, Mumford PA, Venables PJW, Maini RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989;48:7-13.
12. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993;19:123-51.
13. Silman AJ, MacGregor AJ, Thomson W, Holligan S, et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 1993;32:903-7.
14. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205-13.
15. Todd JA, Acha-Orbea H, Bell JI, Chao N, et al. A molecular basis for the MHC class II-associated autoimmunity. Science 1988;240:1003-9.
16. Hammer J, Gallazzi F, Bono F, Karr RW, et al. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med 1995;181:1847-55.
17. Masi AT. Incidence of rheumatoid arthritis: do the observed age-sex interaction patterns support a role of androgenic-anabolic steroid deficiency in its pathogenesis? Br J Rheumatol 1994;33:697.
18. Buchanan WW. Rheumatoid arthritis: another New World disease? Sem Arthritis Rheum 1994;23:289-94.
19. Di Giovine FS, Bailly S, Bootman J, Almond N, Duff GW. Absence of lentiviral and human T cell leukemia viral sequences in patients with rheumatoid arthritis. Arthritis Rheum 1994;37:349-58.
20. Cush JJ, Lipsky PE. Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum 1988;31:1230-8.
21. Firestein G. Rheumatoid synovitis and pannus. In: Klippel JH, Dieppe PA (eds). Rheumatology. St Louis Mosby-Year Book Europe Limited, 1995;12.1-12.30.
22. Allard SA, Muirden KD, Maini RN. Correlation of histopathological features of pannus with patterns of damage in different joints in rheumatoid arthritis. Ann Rheum Dis 1991;50:278-83.
23. Chu CQ, Field M, Allard S, Abney E, et al. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992;31:653-61.
24. Janossy G, Panayi G, Duke O, Bofill M, et al. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 1981;ii:839-41.
25. Klareskog L, Forsum U, Scheynius A, Kabelitz D, Wigzell H. Evidence in support of a self perpetuating HLA-DR dependent delayed type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci USA 1982;79:3632-6.
26. Steeg PS, Moore RN, Johnson HM, Oppenheim JJ. Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity. J Exp Med 1982;156:1780-93.
27. Xu WD, Firestein GS, Taetle R, Kaushansky K, Zvaifler NJ. Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest 1989;83:876-82.
28. Chang RJ, Lee SH. Effects of interferon gamma and tumour necrosis factor alpha on the expression of a Ia antigen on a murine macrophage cell line. J Immunol 1986;137:2853.
29. Hanafusa T, Pujol-Borrell R, Chiovato L, Russell RCG, et al. Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease; relevance for autoimmunity. Lancet 1983;ii: 1111-5.
30. Foulis AK, Farquharson MA, Hardman R. Aberrant expression of HLA-DR antigens by insulin containing beta cells in recent onset Type I (insulin-dependent) diabetes mellitus. Diabetes 1986;35:1215-24.
31. Londei M, Bottazzo GF, Feldmann M. Human T-cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells. Science 1985;228:85-9.
32. Dayan CM, Londei M, Corcoran AE, Grubeck-Loebenstein B, et al. Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. Proc Nat Acad Sci 1991;88:7415-9.
33. Mullins RJ, Cohen SBA, Webb LMC, Chernajovsky Y, et al. Identification of thyroid stimulating hormone receptor specific T cells in Graves' disease thyroid using antoantigen transfected EBV transformed B cell lines. J Clin Invest 1995;96:30-7.
34. Quaratino S, Feldmann M, Dayan CM, Acuto O, Londei M. Human self-reactive T cell clones expressing identical TCR β chains differ in their ability to recognise a cryptic self-epitope. J Exp Med 1996;183:349-58.
35. Burman P, Totterman TH, Oberg K, Anders Karlsson F. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 1986;63:1086-90.
36. Atkins MB, Mier JW, Parkinson DR, Gould JA, et al. Hypothyroidism after treatment with interlenkin-2 and lymphokine-activated killer cells. N Engl J Med 1988;318:1557-63.
37. Panitch HS, Hirsch RL, Schindler J, Johnson KL. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune svstcm. Neurology 1987;37: 1097-1102.
38. Sarvetnick N, Shizuru J, Liggitt D, Martin L, et al. Loss of pancreatic islet tolerance induced by β-cell expression of interferon-γ. Nature 1990;346:844-7.
39. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, et al. Induction of type-1 diabetes by interferon-α and transgenic mice. Science 1993;260:1942-7.
40. Allison J, Malcolm L, Chosich N, Miller JFAP. Inflammation but not autoimmunity occurs in transgenic mice expressing constitutive levels of IL-2 in islet β cells. Eur J Immunol 1992;22: 1115-21.
41. Guerder S, Picarella DE, Linsley PS, Flavell RA. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumour necrosis factor alpha leads to autoimmunity in transgenic mice. Proc Natl Acad Sci USA 1994;91:5138-42.
42. Allison J, Miller J, Sarvetnick N. Cytokines in diabetes. In: Brennan FM, Feldmann M (eds). Cytokines in autoimmunity. Austin, TX: RG Landes, 1996:49-75.
43. Taniguchi T, Ohno S, Fujii-Kuriyama Y, Muramatsu H. The nucleotide sequence of human fibroblast interferon cDNA. Gene 1980;10:11-5.
44. Gray PW, Aggarwal BB, Benton CV, Bringman TS, et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumor necrosis factor activity. Nature 1984;312:721-4.
45. Brennan FM, Feldmann M. Cytokines in autoimmunity. Austin, TX: RG Landes, 1996.
46. Buchan G, Barrett K, Fujita T, Taniguchi T, et al. Detection of activated T cell products in the rheumatoid joint using cDNA probes to interleukin-2 (IL-2) IL-2 receptor and IFN-γ. Clin Exp Immunol 1988;71:295-301.
47. Brennan FM, Chantry D, Jackson AM, Maini RN, Feldmann M. Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun 1989;2(Suppl):177-86.
48. Fontana A, Hentgartner H, Fehr K, Grob PJ, Cohen G. Interleukin-1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 1982;2:49-56.
49. Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci USA 1986;83:8749-53.
50. Saklatvala J, Sarsfield SJ, Townsend Y. Purification of two immunologically different leucocyte proteins that cause cartilage resorption lymphocyte activation and fever. J Exp Med 1985;162:1208-15.
51. Chantry D, Winearls CG, Maini RN, Feldmann M. Mechanism of immune complex mediated damage; induction of interleukin 1 by immune complexes and synergy with interferon γ and tumour necrosis factor α. Eur J Immunol 1989;19:189-92.
52. Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, et al. Tumour necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986;163: 1433-50.
53. Saklatvala J. Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322:547-9.
54. Haworth C, Brennan FM, Chantry D, Turner M, et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 1991;21:2575-9.
55. Butler D, Maini RN, Feldmann M, Brennan FM. Blockade of TNFα with chimeric anti-TNFα monoclonal antibody, cA2 reduces IL-6 and IL-8 release in RA mononuclear cultures: a comparison with IL-1ra. Eur Cytokine Network 1995;6:225-30.
56. Tracey KJ, Vlassara H, Cerami A. Cachectin/tumour necrosis factor. Lancet 1989;i:1122-6.
57. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
58. Miossec P, Naviliat M, D'Angeac AD, Sany J, Banchereau J. Low levels of interleukin-4 and high levels of transforming growth factor β in rheumatoid synovitis. Arthritis Rheum 1990;33:1180-7.
59. Fava R, Olsen N, Keski-Oja J, Moses H, Pincus T. Active and latent forms of transforming growth factor β activity in synovial effusions. J Exp Med 1989;169:291-6.
60. Katsikis P, Chu CQ, Brennan FM, Maini RN, Feldman M. Immunoregulatory role of interleukin (IL-10) in rheumatoid arthritis. J Exp Med 1994;179:1517-27.
61. Brennan FM, Gibbons DL, Mitchell T, Cope AP, et al. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol 1992;22:1907-12.
62. Smith KA. The interleukin 2 receptor. Adv Immunol 1988;42: 165-74.
63. Deleuran BW, Chu CQ Field M, Brennan FM, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum 1992;35:1170-8.
64. Aderka D, Wysenbeek A, Engelmann H, Cope AP, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:1111-21.
65. Cope A, Aderka D, Doherty M, Engelmann H, et al. Soluble-tumour necrosis factor (TNF) receptors are increased in the sera and synovial fluids of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160-9.
66. Brennan FM, Gibbons D, Cope A, Katsikis P, et al. TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNFα action. Scand J Immunol 1995;42:158-65.
67. Williams RO, Feldman M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-8.
68. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, et al. Involvement of endogenous tumour necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992;89:7375-9.
69. Piguet PF, Grau GE, Vesin C, Loetscher H, et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology? 1992;77:510-4.
70. Keffer J, Probert L, Cazlaris H, Georgopoulos S, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
71. Knight DM, Trinh H, Le J, Siegel S, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
72. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFα. Arthritis Rheum 1993;36:1681-90.
73. Maini RN. The Croonian Lecture 1995. The role of cytokines in rheumatoid arthritis. J R Coll Physicians Lond 1996;30:344-51.
74. Maini RN, Elliott MJ, Brennan FM, Williams RO, et al. Monoclonal anti TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995;144:195-223.
75. Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti TNFα therapy of rheumatoid arthritis. Adv Immunol 1996 (in press).
76. Elliott MJ, Maini RN, Feldman M, Long-Fox A, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
77. Elliott MJ, Maini RN, Feldman M, Kalden JR, et al. Randomised double blind comparison of a chimaeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
78. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CD571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
79. Derkx R, Taminiau RS, Stronkhorst A, Wortel C, et al. Tumour necrosis factor antibody treatment in Crohn's disease. Lancet 1993;342:173-4.
80. Van Dullemen HM, Van Deventer SJH, Homes DW, Bijl HA, et al. Treatment of Crohn's disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
81. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, et al. An antibody to lymphotoxin and tumour necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990;172:1193-200.
82. Baker D, Butler D, Scallon BJ, O'Neill JK, et al. Control of established experimental allergic encephalomyelitis by inhibition of tumour necrosis factor activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994;24:2040-8.
83. Sommer N, Loschmann P-A, Northoff GH, Weller M, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995;1:244-8.
84. Genain CP, Roberts T, Davis RL, Nguyen M-H, et al. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA 1995;92:3601-5.
85. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996;39:1082-91.
86. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994;91:2762-6.